Peptides A-Z · Research Guide
This article explains what melittin is and how it is used in research. It summarizes biochemical identity, primary mechanisms, major preclinical uses and the delivery and safety…
The target audience is researchers and informed readers who need a clear, evidence-based overview of melittin for experimental planning. The content draws only on foundational compound records and recent reviews to keep recommendations strictly informational.
melittin is a 26 amino-acid amphipathic peptide derived from the venom of the honeybee Apis mellifera and is commonly described in biochemical databases as a membrane-active, lytic peptide. The sequence length and amphipathic character are central to how the peptide interacts with lipid bilayers, and these foundational identity details are recorded in compound summaries and protein entries that researchers rely on for sequence verification PubChem compound summary.
The amphipathic nature means melittin contains both hydrophobic and hydrophilic regions, which helps it insert into and disrupt lipid membranes. Practical laboratory descriptions note that the peptide can display aggregation and solubility behavior that affects handling and experimental reproducibility, so exact sequence and specification matter when comparing studies UniProt entry for melittin precursor.
Commercial and academic sources supply melittin typically as lyophilized powder for research use. Common formats and basic storage recommendations appear in supplier specifications and database metadata, and researchers generally record lot, purity and solvent conditions to maintain reproducibility across experiments PubChem compound summary.
Because small changes in sequence, formulation or counterions can alter membrane activity, it is important to refer to authoritative compound records for naming and sequence conventions when designing comparative studies UniProt entry for melittin precursor. For background, see our peptides 101 guide.
The primary mechanism of action for this peptide is membrane disruption, where the amphipathic structure enables insertion into lipid bilayers, pore formation and lysis of cells. That membrane-disruptive, or lytic, activity explains much of the compound’s rapid cytotoxicity in cell assays and underlies many experimental applications PubChem compound summary.
Downstream of membrane damage, studies report secondary cellular responses that include apoptosis, activation of immune signalling pathways and, in some cancer models, features consistent with immunogenic cell death. Those downstream effects are often invoked to explain how membrane activity can translate into tumour control in preclinical work Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal modelsmelittin-lipid nanoparticles study.
Because the core mechanism targets lipid membranes rather than a single protein, the same membrane-active properties that enable antimicrobial or anticancer activity also create a risk of off-target cytotoxicity against healthy cells. That mechanistic overlap is why delivery and targeting strategies are central to research designs using the peptide PubChem compound summary.
Preclinical literature shows broad-spectrum antimicrobial activity for melittin in vitro and in animal infection models, and systematic reviews summarize consistent bactericidal and anti‑biofilm effects. These findings have led researchers to test the peptide in contexts where localized antimicrobial action could be useful systematic review of antimicrobial activity.
Because biofilms on medical devices and surfaces are resistant to many conventional antibiotics, melittin and engineered analogues have been evaluated for surface coatings, localized delivery formulations and topical applications that seek to control biofilm formation without systemic exposure systematic review of antimicrobial activity.
melittin is used in research as a membrane-active peptide studied for antimicrobial and anticancer effects; practical use is investigative and depends on formulation and safety testing rather than established clinical application.
Systemic antimicrobial use remains limited by haemolytic activity and delivery challenges. In practice, research emphasis is on localized approaches where antimicrobial potency can be harnessed while limiting contact with circulating red blood cells and other sensitive tissues systematic review of antimicrobial activity.
In preclinical cancer research, melittin shows consistent anticancer activity in cell culture and animal models, achieved through membrane disruption, apoptosis induction and modulation of immune responses that can contribute to tumour reduction in experimental systems Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models.
Typical study models include in vitro viability assays, mechanistic readouts for apoptosis and immune markers, and in vivo tumour growth or survival endpoints in rodent models. Engineered constructs and targeted delivery are commonly paired with these models to test whether tissue selectivity can be improved Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational ChallengesPMC nanoparticle review.
To help researchers determine whether melittin fits a given cancer project, a simple evaluation framework used in reviews recommends checking biological rationale, selecting a delivery strategy early, planning rigorous toxicity assessment and assessing translational value before proceeding to complex animal studies Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models. See our consultation for project-level guidance.
Because haemolysis and off-target membrane damage limit unformulated systemic use, most research relies on engineered delivery methods such as liposomal encapsulation, nanoparticles, PEGylation and pro-peptide or conjugate designs to improve targeting and reduce systemic exposure. Reviews and recent studies outline these strategies and the rationale behind each approach Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational ChallengesMDPI review on nano-delivery.
Liposomes and nanoparticle carriers can sequester melittin until it reaches a target site, and PEGylation or pro-peptide constructs can reduce immediate membrane affinity during circulation. In animal models, properly designed formulations have been shown to lower haemolytic activity while maintaining antitumour or antimicrobial potency at the site of interest Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational Challenges.
When selecting a delivery approach, practical considerations include particle stability, release kinetics, manufacturing complexity and the choice of targeting ligands. Researchers typically include characterization assays for encapsulation efficiency, release under physiological conditions and hemolysis testing as part of preclinical validation Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational Challenges.
A primary and repeatedly documented safety concern for melittin is dose-dependent haemolysis, where red blood cells are damaged because the peptide disrupts lipid membranes. This haemolytic activity constrains systemic dosing and is a persistent focus in safety reviews and experimental reports Toxicon review on safety and haemolytic activity.
Allergic reactions and the potential for anaphylaxis are additional risks with bee-venom derived peptides, and these possibilities are highlighted in case reports and reviews that address clinical safety considerations. Such immune-mediated events are separate from direct membrane toxicity but are relevant for any work involving animal or human exposure UniProt entry for melittin precursor.
Common mitigation strategies used in preclinical research include localized application, targeted delivery vehicles, dose fractionation and extensive hemolysis testing in vitro and in vivo. Each approach reduces but does not eliminate risk, and the limits of mitigation must be explicit when interpreting results or proposing translation Toxicon review on safety and haemolytic activity.
Human clinical trial evidence for melittin itself is minimal as of 2026; most of the promising data remain preclinical or involve engineered melittin constructs rather than unformulated peptide. Translational reviews emphasize that clinical benefit and safety profiles are still unproven without controlled human trials Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models.
The main translational hurdles are standardized human dosing, long-term toxicity data and reproducible targeted delivery in humans. Overcoming formulation, manufacturing and regulatory challenges will be necessary before melittin-based therapies can be tested broadly in patients Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational Challenges.
Typical mistakes include neglecting hemolysis assays when evaluating systemic exposure, undercharacterizing delivery vehicles, and assuming in vitro potency will translate directly to in vivo efficacy. Reviews caution that membrane-acting peptides can appear exceptionally potent in cell assays yet fail in animal models without appropriate formulation Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models.
A concise decision checklist for whether to include melittin in a project is: 1) confirm a biological rationale where membrane activity is appropriate, 2) identify a feasible targeted delivery strategy, 3) plan measurable safety endpoints including hemolysis, and 4) assess translational value compared with alternative approaches Toxicon review on safety and haemolytic activity.
Example scenarios: a local antimicrobial coating study should prioritize surface-binding formulations and biofilm readouts; a targeted tumour model should include encapsulation validation, biodistribution and immune marker panels. Key readouts typically include cell viability, hemolysis assays, encapsulation efficiency and in vivo tumour growth or infection reduction metrics systematic review of antimicrobial activity.
In short, melittin is a membrane-acting peptide with consistent preclinical antimicrobial and anticancer signals but limited human data; its experimental utility depends on careful attention to delivery and safety. Reviews and compound databases remain the primary resources for up-to-date sequence, formulation and safety summaries PubChem compound summary.
Next steps for researchers include consulting recent systematic reviews, verifying compound metadata in authoritative databases, designing experiments that include robust hemolysis and biodistribution readouts, and following the progress of early-phase trials of engineered constructs. Until well-controlled human data are available, melittin use should be considered investigational and confined to appropriate research settings Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models. Find resources at Peptide World.
No. As of 2026 melittin is not an approved therapeutic; most activity remains at the preclinical or early experimental stage.
Key risks are dose-dependent haemolysis, local tissue irritation and allergic reactions; these drive the need for targeted delivery and safety assays.
Systemic use is constrained by haemolytic toxicity and limited human data; research focuses on engineered delivery and localized applications.
Bottom line
Researchers interested in melittin should prioritize authoritative compound records and recent systematic reviews when designing studies, and treat all in vivo or translational plans as experimental. Careful formulation, hemolysis testing and transparent reporting will be essential to advance any clinical translation.